Our top pick for
Building a portfolio
Surmodics, Inc is a diagnostics & research business based in the US. Surmodics shares (SRDX) are listed on the NASDAQ and all prices are listed in US Dollars. Surmodics employs 370 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$33.45 - $59.75|
|50-day moving average||$55.54|
|200-day moving average||$46.00|
|Wall St. target price||$70.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Surmodics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surmodics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surmodics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1184x. In other words, Surmodics shares trade at around 1184x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Surmodics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 15.975. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Surmodics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Surmodics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.4 million.
The EBITDA is a measure of a Surmodics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$94.5 million|
|Gross profit TTM||$29.4 million|
|Return on assets TTM||-0.35%|
|Return on equity TTM||0.55%|
|Market capitalisation||$813.2 million|
TTM: trailing 12 months
There are currently 318,192 Surmodics shares held short by investors – that's known as Surmodics's "short interest". This figure is 9.9% down from 353,244 last month.
There are a few different ways that this level of interest in shorting Surmodics shares can be evaluated.
Surmodics's "short interest ratio" (SIR) is the quantity of Surmodics shares currently shorted divided by the average quantity of Surmodics shares traded daily (recently around 59586.516853933). Surmodics's SIR currently stands at 5.34. In other words for every 100,000 Surmodics shares traded daily on the market, roughly 5340 shares are currently held short.
However Surmodics's short interest can also be evaluated against the total number of Surmodics shares, or, against the total number of tradable Surmodics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surmodics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Surmodics shares in existence, roughly 20 shares are currently held short) or 0.0347% of the tradable shares (for every 100,000 tradable Surmodics shares, roughly 35 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Surmodics.
Find out more about how you can short Surmodics stock.
We're not expecting Surmodics to pay a dividend over the next 12 months.
Surmodics's shares were split on a 2:1 basis on 6 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Surmodics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Surmodics shares which in turn could have impacted Surmodics's share price.
Over the last 12 months, Surmodics's shares have ranged in value from as little as $33.45 up to $59.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surmodics's is 1.0612. This would suggest that Surmodics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Surmodics, Inc. , together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.